Peptide YY (1–36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β‐cell function, growth and survival. Issue 3 (9th December 2019)
- Record Type:
- Journal Article
- Title:
- Peptide YY (1–36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β‐cell function, growth and survival. Issue 3 (9th December 2019)
- Main Title:
- Peptide YY (1–36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β‐cell function, growth and survival
- Authors:
- Lafferty, Ryan A.
Tanday, Neil
McCloskey, Andrew
Bompada, Pradeep
De Marinis, Yang
Flatt, Peter R.
Irwin, Nigel - Abstract:
- Abstract: Aim: To investigate the antidiabetic efficacy of enzymatically stable Peptide YY (PYY) peptides from phylogenetically ancient fish. Materials and methods: N‐terminally stabilized, PYY (1–36) sequences from Amia calva (bowfin), Oncorhynchus mykiss (trout), Petromyzon marinus (sea lamprey) and Scaphirhynchus albus (sturgeon), were synthesized, and both biological actions and antidiabetic therapeutic efficacy were assessed. Results: All fish PYY (1–36) peptides were resistant to dipeptidyl peptidase‐4 (DPP‐4) degradation and inhibited glucose‐ and alanine‐induced ( P < 0.05 to P < 0.001) insulin secretion. In addition, PYY (1–36) peptides imparted significant ( P < 0.05 to P < 0.001) β‐cell proliferative and anti‐apoptotic benefits. Proliferative effects were almost entirely absent in β cells with CRISPR‐Cas9‐induced knockout of Npyr1 . In contrast to human PYY (1–36), the piscine‐derived peptides lacked appetite‐suppressive actions. Twice‐daily administration of sea lamprey PYY (1–36), the superior bioactive peptide, for 21 days significantly ( P < 0.05 to P < 0.001) decreased fluid intake, non‐fasting glucose and glucagon in streptozotocin (STZ)‐induced diabetic mice. In addition, glucose tolerance, insulin sensitivity, pancreatic insulin and glucagon content were significantly improved. Metabolic benefits were linked to positive changes in pancreatic islet morphology as a result of augmented ( P < 0.001) proliferation and decreased apoptosis of β cells.Abstract: Aim: To investigate the antidiabetic efficacy of enzymatically stable Peptide YY (PYY) peptides from phylogenetically ancient fish. Materials and methods: N‐terminally stabilized, PYY (1–36) sequences from Amia calva (bowfin), Oncorhynchus mykiss (trout), Petromyzon marinus (sea lamprey) and Scaphirhynchus albus (sturgeon), were synthesized, and both biological actions and antidiabetic therapeutic efficacy were assessed. Results: All fish PYY (1–36) peptides were resistant to dipeptidyl peptidase‐4 (DPP‐4) degradation and inhibited glucose‐ and alanine‐induced ( P < 0.05 to P < 0.001) insulin secretion. In addition, PYY (1–36) peptides imparted significant ( P < 0.05 to P < 0.001) β‐cell proliferative and anti‐apoptotic benefits. Proliferative effects were almost entirely absent in β cells with CRISPR‐Cas9‐induced knockout of Npyr1 . In contrast to human PYY (1–36), the piscine‐derived peptides lacked appetite‐suppressive actions. Twice‐daily administration of sea lamprey PYY (1–36), the superior bioactive peptide, for 21 days significantly ( P < 0.05 to P < 0.001) decreased fluid intake, non‐fasting glucose and glucagon in streptozotocin (STZ)‐induced diabetic mice. In addition, glucose tolerance, insulin sensitivity, pancreatic insulin and glucagon content were significantly improved. Metabolic benefits were linked to positive changes in pancreatic islet morphology as a result of augmented ( P < 0.001) proliferation and decreased apoptosis of β cells. Sturgeon PYY (1–36) exerted similar but less impressive effects in STZ mice. Conclusion: These observations reveal, for the first time, that PYY (1–36) peptide sequences from phylogenetically ancient fish replicate the pancreatic β‐cell benefits of human PYY (1–36) and have clear potential for the treatment of type 2 diabetes. … (more)
- Is Part Of:
- Diabetes, obesity & metabolism. Volume 22:Issue 3(2020)
- Journal:
- Diabetes, obesity & metabolism
- Issue:
- Volume 22:Issue 3(2020)
- Issue Display:
- Volume 22, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 22
- Issue:
- 3
- Issue Sort Value:
- 2020-0022-0003-0000
- Page Start:
- 404
- Page End:
- 416
- Publication Date:
- 2019-12-09
- Subjects:
- appetite -- bowfin -- degradation -- insulin secretion -- lamprey -- peptide YY (PYY) -- sturgeon -- trout -- β cell
Diabetes -- Periodicals
Obesity -- Periodicals
Metabolism -- Disorders -- Periodicals
Clinical pharmacology -- Periodicals
616.462 - Journal URLs:
- http://www.blackwellpublishing.com/journal.asp?ref=1462-8902&site=1 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1463-1326 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/dom.13908 ↗
- Languages:
- English
- ISSNs:
- 1462-8902
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3579.601970
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17596.xml